2-FXE EU

2F-2′-Oxo-PCE, commonly referred to as 2-FXE, is a dissociative compound within the arylcyclohexylamine class. Structurally, it is a fluorinated analog of deschloroketamine (DCK), closely related to ketamine and methoxetamine (MXE). This research chemical has gained attention for its unique properties stemming from its fluorination, which affects its pharmacokinetics and binding affinity to NMDA receptors.

Mechanism of Action: 2F-2′-Oxo-PCE primarily functions as an NMDA receptor antagonist. By inhibiting the action of glutamate, a major excitatory neurotransmitter in the central nervous system, it disrupts normal neural communication. This interference induces dissociative effects, characterized by sensory detachment, altered perceptions, and reduced physical discomfort.

Effects:

• Dissociative Effects: Profound detachment from physical and mental awareness, ranging from mild sensory distortion to complete dissociative states.
• Euphoria: Users often report a sense of well-being, calm, and pleasure at moderate doses.
• Sensory Alterations: Enhanced or distorted auditory and visual perceptions, including hallucinations.
• Cognitive Changes: Impaired memory, concentration, and logical reasoning.

Dosage Guidelines: Dosage varies based on individual sensitivity, experience, and administration method. Common ranges include:

• Threshold Dose: 2-5 mg
• Light Dose: 5-10 mg
• Common Dose: 10-20 mg
• Strong Dose: 20-30 mg
• Heavy Dose: 30 mg+

Users are advised to start at the lower end of the spectrum and incrementally adjust based on their responses. Effects can intensify with dosage and may lead to overwhelming dissociative experiences at higher levels.

Onset, Duration, and Half-Life:

• Onset: 20-40 minutes (oral), 5-15 minutes (insufflated)
• Peak Effects: 1-2 hours
• Duration: 3-6 hours
• Half-Life: Approximately 6-8 hours, though metabolites may extend subjective effects.

Side Effects:

• Physical: Motor impairment, dizziness, nausea, urinary issues (with prolonged use), and blurred vision.
• Cognitive: Confusion, memory deficits, and slowed thought processes.
• Psychological: Anxiety, paranoia, and potential dependence with chronic use.

Harm Reduction Guidelines:

• Start with minimal doses to assess tolerance.
• Avoid combining with depressants (e.g., alcohol, benzodiazepines) to reduce overdose risks.
• Use in a secure environment with a trusted companion, especially at higher doses.
• Maintain hydration and monitor urinary health.
• Limit frequency of use to minimize long-term risks.

Legal and Ethical Considerations: 2F-2′-Oxo-PCE is intended for research purposes and may not be legally permitted for human use in some jurisdictions. Researchers and users must ensure compliance with local regulations.